Montag A & Associates Inc. lowered its holdings in Zoetis Inc (NYSE:ZTS) by 5.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 22,441 shares of the company’s stock after selling 1,250 shares during the quarter. Montag A & Associates Inc.’s holdings in Zoetis were worth $2,796,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds have also bought and sold shares of ZTS. Bath Savings Trust Co raised its stake in shares of Zoetis by 26.0% in the second quarter. Bath Savings Trust Co now owns 7,293 shares of the company’s stock worth $828,000 after purchasing an additional 1,505 shares during the last quarter. Park National Corp OH raised its stake in shares of Zoetis by 4.0% in the second quarter. Park National Corp OH now owns 110,650 shares of the company’s stock worth $12,558,000 after purchasing an additional 4,271 shares during the last quarter. Private Trust Co. NA raised its stake in shares of Zoetis by 3.7% in the second quarter. Private Trust Co. NA now owns 15,519 shares of the company’s stock worth $1,761,000 after purchasing an additional 556 shares during the last quarter. Dorsey Wright & Associates raised its stake in shares of Zoetis by 7.6% in the second quarter. Dorsey Wright & Associates now owns 4,593 shares of the company’s stock worth $521,000 after purchasing an additional 324 shares during the last quarter. Finally, WINTON GROUP Ltd raised its stake in shares of Zoetis by 2.3% in the second quarter. WINTON GROUP Ltd now owns 7,534 shares of the company’s stock worth $855,000 after purchasing an additional 171 shares during the last quarter. Hedge funds and other institutional investors own 89.95% of the company’s stock.
In other Zoetis news, EVP Roxanne Lagano sold 4,463 shares of the business’s stock in a transaction dated Monday, August 19th. The stock was sold at an average price of $125.99, for a total transaction of $562,293.37. Following the completion of the sale, the executive vice president now owns 33,190 shares of the company’s stock, valued at $4,181,608.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Kristin C. Peck sold 11,500 shares of the business’s stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $123.22, for a total value of $1,417,030.00. Following the sale, the executive vice president now directly owns 48,877 shares of the company’s stock, valued at approximately $6,022,623.94. The disclosure for this sale can be found here. Insiders have sold 34,332 shares of company stock valued at $4,258,182 in the last three months. 0.29% of the stock is currently owned by corporate insiders.
NYSE:ZTS traded down $3.17 during mid-day trading on Friday, hitting $117.86. 3,757,845 shares of the company traded hands, compared to its average volume of 2,125,332. The stock’s fifty day moving average price is $125.46 and its 200-day moving average price is $116.48. Zoetis Inc has a one year low of $78.90 and a one year high of $130.20. The company has a quick ratio of 2.87, a current ratio of 4.17 and a debt-to-equity ratio of 2.74. The firm has a market cap of $57.43 billion, a price-to-earnings ratio of 37.65, a price-to-earnings-growth ratio of 2.98 and a beta of 0.88.
Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, November 7th. The company reported $0.94 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.88 by $0.06. Zoetis had a return on equity of 72.86% and a net margin of 22.74%. The business had revenue of $1.58 billion during the quarter, compared to analyst estimates of $1.58 billion. During the same quarter in the previous year, the company posted $0.83 earnings per share. Zoetis’s revenue for the quarter was up 7.0% on a year-over-year basis. Equities analysts predict that Zoetis Inc will post 3.57 EPS for the current year.
The business also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Tuesday, October 22nd will be issued a dividend of $0.164 per share. This represents a $0.66 annualized dividend and a yield of 0.56%. The ex-dividend date is Monday, October 21st. Zoetis’s dividend payout ratio is presently 21.09%.
ZTS has been the subject of a number of research reports. Stifel Nicolaus set a $140.00 price objective on Zoetis and gave the company a “buy” rating in a research report on Friday, September 13th. Barclays upped their price objective on Zoetis from $120.00 to $135.00 and gave the company an “overweight” rating in a research report on Wednesday, August 7th. Argus set a $140.00 price objective on Zoetis and gave the company a “buy” rating in a research report on Wednesday, September 4th. ValuEngine cut Zoetis from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. Finally, Craig Hallum upped their price objective on Zoetis from $132.00 to $138.00 and gave the company a “buy” rating in a research report on Wednesday, August 7th. Eight investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. Zoetis currently has an average rating of “Buy” and an average price target of $126.75.
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Read More: What is the Dividend Aristocrat Index?
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.